Utilization and efficacy of elbasvir/grazoprevir for treating hepatitis C virus infection after liver transplantation

Development of Duodenal Ulcers due to the Discontinuation of Proton Pump Inhibitors After the Induction of Sofosbuvir Plus Ledipasvir Therapy: A Report of Two Cases

(2018) S. Miuma et al.   TRANSPLANTATION PROCEEDINGS

Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis

(2017) Ira M. Jacobson et al.   GASTROENTEROLOGY

Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study

(2017) Varun Saxena et al.   HEPATOLOGY

Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis C virus infection and pre-existing renal disease

(2017) K. Rajender Reddy et al.   HEPATOLOGY RESEARCH

Elbasvir/Grazoprevir Use in Postliver Transplantation Patients on Hemodialysis

(2017) Michelle T. Martin et al.   TRANSPLANTATION

Cost-Utility of Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1 Infection

(2017) Shelby Corman et al.   VALUE IN HEALTH

Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response

(2016) Norah A. Terrault et al.   GASTROENTEROLOGY

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

(2016) Fred Poordad et al.   HEPATOLOGY

Hepatitis C Disease Burden in the United States in the era of oral direct-acting antivirals

(2016) Jagpreet Chhatwal et al.   HEPATOLOGY

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study

(2016) Hiromitsu Kumada et al.   JOURNAL OF GASTROENTEROLOGY

NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b

(2016) Eiichi Ogawa et al.   JOURNAL OF GASTROENTEROLOGY

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial

(2016) Jan Sperl et al.   JOURNAL OF HEPATOLOGY

Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study

(2016) E. B. Tapper et al.   JOURNAL OF VIRAL HEPATITIS

Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies

(2016) M. Mizokami et al.   JOURNAL OF VIRAL HEPATITIS

Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial

(2016) Michael Manns et al.   LANCET INFECTIOUS DISEASES

Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis

(2015) P. A. Cortesi et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

(2015) Stefan Zeuzem et al.   ANNALS OF INTERNAL MEDICINE

Hepatitis C Virus Treatment: Is It Possible To Cure All Hepatitis C Virus Patients?

(2015) Andrew J. Muir et al.   Clinical Gastroenterology and Hepatology

Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease

(2015) Michael Charlton et al.   GASTROENTEROLOGY

Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy

(2015) Jun Itakura et al.   HEPATOLOGY RESEARCH

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial

(2015) Eric Lawitz et al.   LANCET

Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4–5 chronic kidney disease (the C-SURFER study): a combination phase 3 study

(2015) David Roth et al.   LANCET

Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation

(2015) Yoshihide Ueda et al.   TRANSPLANT INTERNATIONAL

Directly Acting Antivirals (DAAs) for the Treatment of Chronic Hepatitis C Virus Infection in Liver Transplant Patients: “A Flood of Opportunity”

(2014) E. J. Gane et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Significance of miRNA-122 in chronic hepatitis C patients with serotype 1 on interferon therapy

(2014) Yasuhiro Kamo et al.   HEPATOLOGY RESEARCH

Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir

(2013) Fiona McPhee et al.   HEPATOLOGY

Management of the Transplant Recipient with Chronic Hepatitis C

(2012) James R. Burton et al.   Clinics in Liver Disease

Treatment of recurrent HCV infection following liver transplantation: Results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNα-2a plus ribavirin

(2012) Yvon Calmus et al.   JOURNAL OF HEPATOLOGY

Long-term Outcomes After Treatment With Interferon and Ribavirin in HCV Patients

(2009) Andrew Aronsohn et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Impact of Pegylated Interferon and Ribavirin Treatment on Graft Survival in Liver Transplant Patients with Recurrent Hepatitis C Infection

(2008) B. J. Veldt et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin

(2008) Marina Berenguer   JOURNAL OF HEPATOLOGY